Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.

Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Siedlar M, Grodzicki T.

Scand J Rheumatol. 2014;43(1):43-8. doi: 10.3109/03009742.2013.805241. Epub 2013 Sep 8.

PMID:
24447112
2.

Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?

Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB, de Oliveira RM, Silva CA, Bonfa E, Pereira RM.

Arthritis Res Ther. 2012 Oct 12;14(5):R216. doi: 10.1186/ar4055.

3.

Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.

Klingberg E, Nurkkala M, Carlsten H, Forsblad-d'Elia H.

J Rheumatol. 2014 Jul;41(7):1349-56. doi: 10.3899/jrheum.131199.

PMID:
24931960
4.

Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy.

Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, Kim HA, Choi HJ, Park W.

Rheumatol Int. 2012 Aug;32(8):2523-7. doi: 10.1007/s00296-011-1981-0. Epub 2011 Jul 16.

PMID:
21833531
5.

Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.

Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N.

BMC Musculoskelet Disord. 2012 Oct 2;13:191. doi: 10.1186/1471-2474-13-191.

6.

High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage.

Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Kucharska E, Grodzicki T.

BMC Musculoskelet Disord. 2013 Mar 19;14:99. doi: 10.1186/1471-2474-14-99.

7.

Sclerostin and Dkk-1 in patients with ankylosing spondylitis.

Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz AE, Guler H, Turhanoglu AD.

Acta Reumatol Port. 2014 Apr-Jun;39(2):146-51.

8.

[Correlation between sclerostin level and radiographic changes in patients with ankylosing spondylitis].

Xie J, Yu X.

Zhonghua Yi Xue Za Zhi. 2015 May 5;95(17):1300-4. Chinese.

PMID:
26081658
9.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

10.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

11.

Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.

Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, Wei Q, Zhang YL, Li T, Jin O, Huang J, Pan Y, Wu Y, Deng X, Gu J.

Int J Rheum Dis. 2012 Aug;15(4):358-65. doi: 10.1111/j.1756-185X.2012.01734.x. Epub 2012 May 23. Erratum in: Int J Rheum Dis. 2012 Dec;15(6):564.

PMID:
22898215
12.

[Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].

Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.

Zhonghua Yi Xue Za Zhi. 2006 Sep 19;86(35):2451-4. Chinese.

PMID:
17156669
13.

An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Pham T, Landewé R, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D.

Ann Rheum Dis. 2006 Dec;65(12):1620-5. Epub 2006 Feb 7.

14.

The VEGF and BMP-2 levels in patients with ankylosing spondylitis and the relationship to treatment with tumour necrosis factor alpha inhibitors.

Tošovský M, Bradna P, Andrýs C, Andrýsová K, Cermáková E, Soukup T.

Acta Medica (Hradec Kralove). 2014;57(2):56-61. doi: 10.14712/18059694.2014.40.

15.

Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.

Sakellariou GT, Anastasilakis AD, Bisbinas I, Oikonomou D, Gerou S, Polyzos SA, Sayegh FE.

Rheumatology (Oxford). 2015 May;54(5):908-14. doi: 10.1093/rheumatology/keu425. Epub 2014 Oct 27.

PMID:
25349442
16.

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.

Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.

Ann Rheum Dis. 2008 Sep;67(9):1276-81. Epub 2007 Nov 15.

PMID:
18006539
17.

Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.

Wendling D, Cedoz JP, Racadot E.

Joint Bone Spine. 2008 Oct;75(5):559-62. doi: 10.1016/j.jbspin.2008.01.026.

PMID:
18674944
18.

Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis.

de Andrade KR, de Castro GR, Vicente G, da Rosa JS, Nader M, Pereira IA, Fröde TS.

Int Immunopharmacol. 2014 Aug;21(2):481-6. doi: 10.1016/j.intimp.2014.05.031. Epub 2014 Jun 9.

PMID:
24925756
19.

Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.

Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP.

Arthritis Rheum. 2010 Jan;62(1):150-8. doi: 10.1002/art.27231.

20.

The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.

Kang KY, Lee KY, Kwok SK, Ju JH, Park KS, Hong YS, Kim HY, Park SH.

Joint Bone Spine. 2011 Mar;78(2):188-93. doi: 10.1016/j.jbspin.2010.05.010.

PMID:
20621536

Supplemental Content

Support Center